



## **P & T COMMITTEE MEETING**

### **Agenda**

**January 7, 2014**

**1:00 pm – 5:00 p.m.**

**225 E. 16<sup>th</sup> Avenue, 1<sup>st</sup> Floor Conference Room, Denver, Colorado**

#### **Unfinished Business and General Orders**

1. Approval of minutes from the October 8, 2013 P&T Meeting
2. Update on Antiherpetics
3. Update on Fluoroquinolones
4. Update on Antiemetics
5. Update on New Generation Antidepressants
6. Update on Antiplatelets
7. Update on Pancreatic enzymes
8. Update on Proton Pump Inhibitors
9. Update on Pulmonary Arterial Hypertension Therapies
10. Update on Targeted Immune Modulators for Rheumatoid Arthritis
11. Update on Triptans

#### **New Business**

##### **Drug Classes Up for Review:**

- Insulins
- Alzheimer's agents
- Atypical antipsychotics
- Growth hormones
- Intranasal corticosteroids
- Leukotriene modifiers
- Multiple Sclerosis agents
- Ophthalmic allergy
- Sedative/hypnotics (non benzodiazepine)
- Statins and Statin combinations

#### **Each Review will contain:**

- Drug class Overview and Agents up for review for each Drug Class
- Oral presentation by manufacturers, providers, and public following overview
- Committee Discussion and Recommendations for each Class

**Upcoming Meeting Date:** Tuesday, April 8, 2014; 1:00 p.m. – 5:00 p.m.

**Interested parties who want to present at the meeting are encouraged to give advanced notice. Please contact Swaniece Grubb at 303-866-3614 or by email at [Swaniece.grubb@state.co.us](mailto:Swaniece.grubb@state.co.us). Written public comments can be submitted to [pdl@state.co.us](mailto:pdl@state.co.us) and will be distributed to all present P&T Committee Members.**